1. Home
  2. HNRG vs OMER Comparison

HNRG vs OMER Comparison

Compare HNRG & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HNRG

Hallador Energy Company

HOLD

Current Price

$14.76

Market Cap

743.5M

Sector

Energy

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$20.08

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HNRG
OMER
Founded
1949
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Coal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
743.5M
844.6M
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
HNRG
OMER
Price
$14.76
$20.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$25.38
★ $32.50
AVG Volume (30 Days)
611.0K
★ 1.5M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 116.78
98.15
EPS
N/A
★ 0.77
Revenue
★ $469,466,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$12.12
$233.22
P/E Ratio
★ N/A
$26.14
Revenue Growth
★ 16.09
N/A
52 Week Low
$13.65
$4.06
52 Week High
$24.70
$21.24

Technical Indicators

Market Signals
Indicator
HNRG
OMER
Relative Strength Index (RSI) 42.96 62.23
Support Level $13.80 $18.00
Resistance Level $16.97 N/A
Average True Range (ATR) 0.60 0.89
MACD -0.09 0.02
Stochastic Oscillator 23.47 74.58

Price Performance

Historical Comparison
HNRG
OMER

About HNRG Hallador Energy Company

Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: